Mary K. Moreland - 18 Feb 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
18 Feb 2022
Net transactions value
-$140,337
Form type
4
Filing time
23 Feb 2022, 19:23:45 UTC
Previous filing
03 Aug 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +15,813 +22% $0.000000 88,158 18 Feb 2022 Direct F1
transaction ABT Common shares without par value Tax liability $92,614 -793 -0.9% $116.79 87,365 22 Feb 2022 Direct
transaction ABT Common shares without par value Sale $47,723 -400 -0.46% $119.31 86,965 22 Feb 2021 Direct F2
holding ABT Common shares without par value 10,986 18 Feb 2022 Profit Sharing Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +73,696 $0.000000 73,696 18 Feb 2022 Common Shares 73,696 $117.58 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
F4 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.

Remarks:

The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).